Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial
Open Access
- 1 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (36) , 3402-3413
Abstract
The presence of pulmonary hypertension (PH) severely aggravates the clinical course of heart failure with preserved ejection fraction (HFpEF). To date, neither established heart failure therapies nor pulmonary vasodilators proved beneficial. This study investigated the efficacy of chronic treatment with the oral soluble guanylate cyclase stimulator riociguat in patients with PH-HFpEF. The phase IIb, randomized, double-blind, placebo-controlled, parallel-group, multicentre DYNAMIC trial assessed riociguat in PH-HFpEF. Patients were recruited at five hospitals across Austria and Germany. Key eligibility criteria were mean pulmonary artery pressure ≥25 mmHg, pulmonary arterial wedge pressure >15 mmHg, and left ventricular ejection fraction ≥50%. Patients were randomized to oral treatment with riociguat or placebo (1:1). Patients started at 0.5 mg three times daily (TID) and were up-titrated to 1.5 mg TID. The primary efficacy endpoint was change from baseline to week 26 in cardiac output (CO) at rest, measured by right heart catheterization. Primary efficacy analyses were performed on the full analysis set. Fifty-eight patients received riociguat and 56 patients placebo. After 26 weeks, CO increased by 0.37 ± 1.263 L/min in the riociguat group and decreased by −0.11 ± 0.921 L/min in the placebo group (least-squares mean difference: 0.54 L/min, 95% confidence interval 0.112, 0.971; P = 0.0142). Five patients dropped out due to riociguat-related adverse events but no riociguat-related serious adverse event or death occurred. The vasodilator riociguat improved haemodynamics in PH-HFpEF. Riociguat was safe in most patients but led to more dropouts as compared to placebo and did not change clinical symptoms within the study period. A total of 114 consecutive patients with pulmonary hypertension associated with heart failure and preserved ejection fraction were randomized to receive riociguat (Rio) or placebo. Riociguat is an orally administered drug that stimulates soluble guanylate cyclase (sGC) directly, independent of nitric oxide, and also sensitizes sGC to endogenous nitric oxide. Stimulation of sGC results in an increase of the cyclic guanosine monophosphate (cGMP) concentration which leads to vasorelaxation. After 26 weeks, the primary efficacy endpoint—cardiac output (CO) at rest measured by right heart catheterization—improved significantly in response to riociguat, along with other haemodynamic parameters.Keywords
Funding Information
- Medical University of Vienna
- M.A.R.C.O. GmbH & Co. KG
This publication has 34 references indexed in Scilit:
- Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection FractionCirculation, 2012
- Pulmonary Hypertension in Heart Failure With Preserved Ejection FractionCirculation, 2011
- Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary DiseaseCirculation, 2011
- Riociguat for the treatment of pulmonary hypertensionExpert Opinion on Investigational Drugs, 2011
- Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: A systematic review of the literatureRespiratory Medicine, 2010
- Pulmonary Hypertension in Heart Failure With Preserved Ejection FractionJACC, 2009
- First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertensionEuropean Respiratory Journal, 2009
- Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart FailureHypertension, 2007
- Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1995
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990